Evidence map›Paper›PMID 32054150›Full record

ArticleCancer research and treatment2020

Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy.

Jeongshim Lee, Jee Suk Chang, Mi Ryung Roh, Minkyu Jung, Choong-Kun Lee, Byung Ho Oh, Kee Yang Chung, Woong Sub Koom, Sang Joon Shin

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04017897 (The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04017897 phase2unknown statusnot on this map

The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma

TypeinterventionalSponsorYonsei UniversityRan2019 to 2022Enrolled52ConditionsMelanomaArmsThe combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Current therapeutic options for gastric adenocarcinoma.Saudi journal of biological sciences · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jeongshim LeeDepartment of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea.
Jee Suk ChangDepartment of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea.
Mi Ryung RohDepartment of Dermatology, Yonsei University College of Medicine, Seoul, Korea.
Minkyu JungDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Choong-Kun LeeDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Byung Ho OhDepartment of Dermatology, Yonsei University College of Medicine, Seoul, Korea.
Kee Yang ChungDepartment of Dermatology, Yonsei University College of Medicine, Seoul, Korea.
Woong Sub KoomDepartment of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea.
Sang Joon ShinDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Yonsei University · KR

Funding

Yonsei University College of Medicine 6-2018-0163
6 · The paper itself

Abstract

purposeWe investigated the clinical efficacy of immune checkpoint blocker (ICB) therapy for metastatic or advanced melanoma in Korean patients. As well, we assessed whether the effects of ICBs can be enhanced by combination therapy with palliative radiotherapy (RT). MATERIALS AND

methodsWe retrospectively reviewed the records of 127 patients with metastatic melanoma who received ICB with or without palliative RT between 2014 and 2018. The melanoma subtypes were classified as follows: chronic sun-damaged (CSD), acral, mucosal, and uveal. The primary endpoint was the objective response rate (ORR).

resultsThe overall ORR was 15%, with 11 complete and eight partial responses. ORRs for CSD, acral/mucosal, and uveal melanomas were 50%, 16.5%, and 0%, respectively (p=0.009). In addition to the subtype, stage at treatment, total tumor burden at treatment, and ICB type were significantly associated with ORR (all p < 0.05). Palliative RT was administered in 44% of patients during the treatment, and it did not affect ORR. Clinical responders to ICB therapy exhibited significantly higher 1-year progression-free and overall survival rates than nonresponders.

conclusionORR for ICB monotherapy in Korean patients with melanoma is relatively modest compared with that in Western patients because the non-CSD subtypes are predominant in the Korean population. Our findings regarding combination therapy with ICB provided a rationale for the initiation of our phase II study (NCT04017897).

Indexed as

Patient SelectionAdolescentAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansImmune Checkpoint InhibitorsMaleMelanomaMiddle AgedPrognosisRepublic of KoreaRetrospective StudiesSurvival RateImmune Checkpoint InhibitorsAsiaImmune checkpoint blockerImmunotherapyMelanoma

Identifiers

PMID32054150
PMCPMC7373866
OpenAlexW3005599097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.